Matthieu Delaye: Intrahepatic cholangiocarcinoma trends and treatment lines
Matthieu Delaye, Head of Clinic in Medical Oncology at the Curie Institute, shared a paper he and his colleagues authored on LinkedIn:
“Intrahepatic cholangiocarcinoma (iCCA) trends and treatment lines: real-world evidence from the French National Hospital Discharge database
Just published in ESMO Gastrointestinal Oncology.
Our work conducted on the French National Hospital Discharge Database, used the artificial intelligence algorithm ATLAS to identified treatment lines.
Our results:
– 13491 patients analysed
– Increased incidence of iCCA in France between 2016 and 2021
– Documentation of real-world duration of first, second, third, fourth- line of treatment
– Possibility of calculating real-world PFS and OS
– Confirmarion of the poor outcome of patients with iCCA on L1 systemic therapy (patients treated before the era of cisgem + ICI)
– Low proportion of patients receiving an L2 and subsequent lines
However:
– Limited to hospital data
– Depend of the quality of medical coding
– Need to be updated to generate data with first-line durvalumab and pembrolizumab
Huge thanks to Benjamin Grenier, Astrid Lievre and Cindy Neuzillet.”
Authors: Matthieu Delaye et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023